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Real-World Therapies and the Problem of Vivax Malaria
J. Kevin Baird, Ph.D.
Wellems and Miller1 wrote of two worlds of malaria: one, of the residents of rural tropical areas
in which the disease is endemic, and the other,
of travelers to those areas, who typically have
greater resources. The distinction is sharp, valid,
and important in considering the development
of tools to combat the global burden of malaria.
Drugs considered safe and effective in one world
may not be so in the other.2 The majority of the
hundreds of millions of people in whom malaria
will develop over the next year will obtain and
consume antimalarial medication without medical
supervision. Although the licensing of complex
or poorly tolerated therapeutic regimens requiring clinical screening for contraindications may
be perfectly suitable for populations with access
to close clinical supervision, distributing the
same regimen in the rural tropics is reckless.
Two other worlds of malaria are those with
and without endemic Plasmodium vivax. Vivax malaria was known as “benign tertian malaria” for
more than a century and is still viewed as rarely
dangerous; evidence suggests a historical underestimation of both the burden of disease and the
potential for death with P. vivax infection.3-7 Endemic vivax malaria occurs throughout the tropics, except where there is a natural absence of
anopheline mosquitoes (east of Vanuatu in the
South Pacific) or among populations lacking the
Duffy receptor on red cells (in much of Africa).
Vivax malaria stands alone among the plasmodia infecting humans in its capacity to reach well
into the temperate latitudes, as it does today —
up to the Korean peninsula and across the southern temperate latitudes of Asia to the Mediterranean Sea. Approximately 2.6 billion people are at
risk, and estimates of annual infections range
from 70 to 390 million,3,4 with about 80% occurring in South and Southeast Asia. Vivax malaria
accounts for at least 70% of the malaria burden
in the Americas.
n engl j med 359;24

Objective examination of the clinical evidence
underpinning available therapies for P. vivax infection reveals a conspicuous neglect of this para
site.5 More importantly, the analytical tools for
critically assessing experimental or standard therapies may be considered insufficient, at best, for
the task of identifying the treatments that are
safe and effective and capable of reducing the
disease burden of vivax malaria.
The distinction between the worlds of malaria with and without P. vivax finds expression
in the study by Karunajeewa et al.8 (Australian
New Zealand Clinical Trials Registry number,
ACTRN12605000550606) reported in this issue
of the Journal. This state-of-the-art clinical trial
evaluates the safety, tolerability, and efficacy of
therapeutic options among young children exposed to endemic falciparum and vivax malaria
in Papua New Guinea. By virtue of the analytical
tools applied, the findings with regard to P. falciparum provide useful insights. The estimated 88%
efficacy of dihydroartemisinin–piperaquine falls
well below other estimates of efficacy for this
combination against this parasite. The authors
point to both suboptimal absorption of piperaquine and to cross-resistance between chloroquine and piperaquine by local parasites in vitro
as a possible basis for the relatively poor performance of the drug combination. Their carefully
assembled evidence makes a compelling case for
the selection of artemether–lumefantrine for
treatment of uncomplicated falciparum malaria
in northwestern Papua New Guinea.
The authors have much less analytical leverage
with regard to the data on P. vivax, however. The
liver stage of P. vivax responsible for relapse (the
hypnozoite) casts a nearly opaque shadow of
ambiguity across the data. The curve showing
occurrences of recrudescent infection provides
almost no useful information for discerning the
advantage of one therapeutic option over another:
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all appear highly effective in the week after
treatment and uniformly poor thereafter. Dihydro
artemisinin–piperaquine appears to be the least
inadequate of the four, but this may be an illusion
created by successfully suppressed relapse. The
authors did not correct the data for post-therapy
reinfection or relapse using a polymerase-chainreaction (PCR) assay, because no existing assay
can achieve such a correction. Nor did they examine parasite responses to these drugs in vitro,
because no standardized protocol for doing so
exists, and experimental protocols yield findings
that are notoriously difficult to interpret.9,10 The
authors cannot assign an attributable risk of reinfection as compared with relapse among their
subjects, because there are no baseline data for
doing so. Even if the authors had applied primaquine against hypnozoites, the only drug currently approved and available for this use, they
could not have assumed its good efficacy, because
there are no data to support that contention.
The data presented by Karunajeewa et al.
should nonetheless alert public health and health
care providers alike to the substantial health burden imposed by hypnozoites. One third of the
children with P. falciparum infection in this study
had recurrent P. falciparum parasitemia within 42
days after the start of treatment. Almost two
thirds of those cases proved to be reinfections,
suggesting a 6-week cumulative incidence of new
infections of about 20%. Incidence-density studies in nearby Western New Guinea consistently
found new P. falciparum infections to outnumber
new P. vivax infections by about 2:1.11,12 The
6-week cumulative incidence of new P. vivax infections in the study by Karunajeewa et al. may be
thus crudely estimated at less than 10%, whereas the realized cumulative incidence of recurrent
P. vivax parasitemia was about 65%. During the
follow-up period, P. vivax parasitemia developed
in almost half of the subjects treated for acute
falciparum malaria. The hypnozoite appears to
be the overwhelmingly dominant source of new
parasitemia and the consequent opportunities for
disease and further transmission.
For operational malarial control, attacking the
hypnozoite may be more effective in relieving
disease burdens than measures minimizing human contact with anopheline mosquitoes. What
can be said of primaquine, the only drug available for eliminating this source of vivax malaria?
Primaquine has been in continuous use for more
2602
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than 50 years. Standard therapy is implemented
over 14 days. Good tolerability requires that a
snack or meal be taken with the drug. Safe administration requires that pregnancy and glucose6-phosphate dehydrogenase deficiency are ruled
out, by means of clinical and laboratory screening. Mechanisms of the drug’s toxicity and activity
are not known. There is no standardized means
of gauging its efficacy against hypnozoites. No
body of current clinical data show that it has
good efficacy in the field, and it may have no efficacy against hypnozoites unless administered
with an appropriate companion drug.13-15
The inadequacy of primaquine and its critical
importance in attacking vivax malaria symbolizes
the technical poverty of the malaria world that
includes P. vivax. If we are to remove the barriers
separating the two worlds of malaria identified
by Wellems and Miller, we must deal with the
control of vivax malaria, and perhaps its eradication. It seems likely that this will prove unmanageable without a safe, practical, and effective
therapy aimed at the hypnozoite.
No potential conflict of interest relevant to this article was
reported.
This article (10.1056/NEJMe0808729) was published at www.
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